PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis

NASDAQ:PCRX • US6951271005

23.02 USD
+0.28 (+1.23%)
At close: Feb 18, 2026
23.02 USD
0 (0%)
After Hours: 2/18/2026, 5:20:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

PCRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. PCRX scores excellent on profitability, but there are some minor concerns on its financial health. PCRX is cheap, but on the other hand it scores bad on growth. With these ratings, PCRX could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year PCRX was profitable.
  • PCRX had a positive operating cash flow in the past year.
  • PCRX had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years PCRX had a positive operating cash flow.
PCRX Yearly Net Income VS EBIT VS OCF VS FCFPCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

  • With an excellent Return On Assets value of 1.65%, PCRX belongs to the best of the industry, outperforming 81.15% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 2.95%, PCRX belongs to the top of the industry, outperforming 82.20% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 3.63%, PCRX belongs to the best of the industry, outperforming 82.20% of the companies in the same industry.
  • PCRX had an Average Return On Invested Capital over the past 3 years of 4.30%. This is significantly below the industry average of 12.64%.
Industry RankSector Rank
ROA 1.65%
ROE 2.95%
ROIC 3.63%
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
PCRX Yearly ROA, ROE, ROICPCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • PCRX's Profit Margin of 2.99% is amongst the best of the industry. PCRX outperforms 80.10% of its industry peers.
  • With an excellent Operating Margin value of 8.88%, PCRX belongs to the best of the industry, outperforming 81.15% of the companies in the same industry.
  • In the last couple of years the Operating Margin of PCRX has grown nicely.
  • PCRX has a better Gross Margin (79.17%) than 84.29% of its industry peers.
  • In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
Industry RankSector Rank
OM 8.88%
PM (TTM) 2.99%
GM 79.17%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
PCRX Yearly Profit, Operating, Gross MarginsPCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
  • Compared to 1 year ago, PCRX has less shares outstanding
  • The number of shares outstanding for PCRX has been increased compared to 5 years ago.
  • Compared to 1 year ago, PCRX has a worse debt to assets ratio.
PCRX Yearly Shares OutstandingPCRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PCRX Yearly Total Debt VS Total AssetsPCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 1.90 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • PCRX has a Altman-Z score of 1.90. This is in the better half of the industry: PCRX outperforms 61.78% of its industry peers.
  • PCRX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as PCRX would need 3.03 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 3.03, PCRX belongs to the best of the industry, outperforming 91.10% of the companies in the same industry.
  • PCRX has a Debt/Equity ratio of 0.52. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.52, PCRX is not doing good in the industry: 62.83% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 3.03
Altman-Z 1.9
ROIC/WACC0.46
WACC7.82%
PCRX Yearly LT Debt VS Equity VS FCFPCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

  • PCRX has a Current Ratio of 5.26. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 5.26, PCRX is doing good in the industry, outperforming 64.92% of the companies in the same industry.
  • PCRX has a Quick Ratio of 3.78. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.78, PCRX perfoms like the industry average, outperforming 59.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 3.78
PCRX Yearly Current Assets VS Current LiabilitesPCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for PCRX have decreased by -6.90% in the last year.
  • PCRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.96% yearly.
  • The Revenue for PCRX has decreased by -16.85% in the past year. This is quite bad
  • The Revenue has been growing by 10.73% on average over the past years. This is quite good.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%

3.2 Future

  • Based on estimates for the next years, PCRX will show a small growth in Earnings Per Share. The EPS will grow by 7.01% on average per year.
  • The Revenue is expected to grow by 6.79% on average over the next years.
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.79%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PCRX Yearly Revenue VS EstimatesPCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
PCRX Yearly EPS VS EstimatesPCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 7.75, the valuation of PCRX can be described as very cheap.
  • 94.24% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of PCRX to the average of the S&P500 Index (27.27), we can say PCRX is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 6.62, the valuation of PCRX can be described as very cheap.
  • PCRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PCRX is cheaper than 93.72% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.16. PCRX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 7.75
Fwd PE 6.62
PCRX Price Earnings VS Forward Price EarningsPCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaper than 95.81% of the companies in the same industry.
  • 94.76% of the companies in the same industry are more expensive than PCRX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 7.62
EV/EBITDA 6.25
PCRX Per share dataPCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.56
EPS Next 2Y4.05%
EPS Next 3Y6.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (2/18/2026, 5:20:00 PM)

After market: 23.02 0 (0%)

23.02

+0.28 (+1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners114.44%
Inst Owner Change-0.98%
Ins Owners0.79%
Ins Owner Change16.54%
Market Cap946.12M
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target30.31 (31.67%)
Short Float %19.55%
Short Ratio8.74
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)0%
PT rev (3m)-20.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.78%
EPS NY rev (1m)-0.31%
EPS NY rev (3m)2.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.65%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.99%
Valuation
Industry RankSector Rank
PE 7.75
Fwd PE 6.62
P/S 1.32
P/FCF 7.62
P/OCF 6.69
P/B 1.3
P/tB 2.92
EV/EBITDA 6.25
EPS(TTM)2.97
EY12.9%
EPS(NY)3.48
Fwd EY15.1%
FCF(TTM)3.02
FCFY13.13%
OCF(TTM)3.44
OCFY14.95%
SpS17.44
BVpS17.69
TBVpS7.9
PEG (NY)N/A
PEG (5Y)0.56
Graham Number34.39
Profitability
Industry RankSector Rank
ROA 1.65%
ROE 2.95%
ROCE 5.34%
ROIC 3.63%
ROICexc 4.58%
ROICexgc 7.99%
OM 8.88%
PM (TTM) 2.99%
GM 79.17%
FCFM 17.33%
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 3.03
Debt/EBITDA 2.44
Cap/Depr 18.95%
Cap/Sales 2.4%
Interest Coverage 4.07
Cash Conversion 91.52%
Profit Quality 579.36%
Current Ratio 5.26
Quick Ratio 3.78
Altman-Z 1.9
F-Score7
WACC7.82%
ROIC/WACC0.46
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.79%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year1.3%
EBIT Next 3Y6.32%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%

PACIRA BIOSCIENCES INC / PCRX FAQ

What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?

ChartMill assigns a fundamental rating of 6 / 10 to PCRX.


What is the valuation status for PCRX stock?

ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.


How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?

PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.


What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 7.75 and the Price/Book (PB) ratio is 1.3.